ROCKET AF

RE-LY

ACTIVE W

AMADEUS

SPORTIF V

Number of patients randomized

14,269

18,113

6,706

4,576

3,922

Therapy under investigation

Rivaroxaban

Dabigatran

Clopidogrel+ASA

Idraparinux

Ximelegatran

Patient characteristics

Age at randomization, (years)

73.1

71.5

70.2

70.1

71.6

Female (%)

40

36

33

34

31

Patient risk at baseline (%)

Atrial fibrillation diagnosed within last year

25.5

N/A

20
6 months – 2 years

N/A

16

ASA use prior to randomization (%)

38

40

28

N/A

18

VKA use prior to screening (%)

62

50

77

76

84

CHADS₂ score

0–1

0.4

31.9

41

25

2

13.3

35.6

Median 2.0

32

31

≥3

86.3

32.4

27

44

Risk factors (%)

Congestive heart failure or LVEF ≤35%

63.0

32.0

30.3

23.4

39

Hypertension

90.4

78.9

82.3

77

81

Age ≥75 years

43.8

31

42

Diabetes mellitus

39.8

23.3

21

9.5

19

Prior stroke, TIA or non-CNS systemic embolism

54.8

19.9

15

23.9

18